

main nodes :

40

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
26 27 28 29 30 31 32 33 41 42 43 44 45 46

main bonds :

7-40 8-41

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 10-11 10-15 11-12 12-13 13-14 14-15
16-17 16-21 17-18 18-19 19-20 20-21 22-23 22-27 23-24 24-25 25-26 26-27 28-29
28-33 29-30 30-31 31-32 32-33 41-42 41-46 42-43 43-44 44-45 45-46

exact/norm bonds :

5-7 6-9 7-8 7-40 8-9

exact bonds :

8-41

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15 16-17 16-21 17-18
18-19 19-20 20-21 22-23 22-27 23-24 24-25 25-26 26-27 28-29 28-33 29-30 30-31
31-32 32-33 41-42 41-46 42-43 43-44 44-45 45-46

isolated ring systems :

containing 1 : 10 : 16 : 22 : 28 :

1:[*1],[*2],[*3],[*4]










match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom
32:Atom 33:Atom 40:CLASS 41:Atom 42:Atom 43:Atom 44:Atom 45:Atom 46:Atom

10/601,690

=>

Uploading C:\Program Files\Common Files\System\Mapi\1033\NT\10601690.str



chain nodes :

40

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 31 32 33 41 42 43 44 45 46

chain bonds :

7-40 8-41

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 10-11 10-15 11-12 12-13 13-14
14-15 16-17 16-21 17-18 18-19 19-20 20-21 22-23 22-27 23-24 24-25 25-26
26-27 28-29 28-33 29-30 30-31 31-32 32-33 41-42 41-46 42-43 43-44 44-45
45-46

10/601,690

exact/norm bonds :
5-7 6-9 7-8 7-40 8-9
exact bonds :
8-41
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15 16-17
16-21 17-18 18-19 19-20 20-21 22-23 22-27 23-24 24-25 25-26 26-27 28-29
28-33 29-30 30-31 31-32 32-33 41-42 41-46 42-43 43-44 44-45 45-46
isolated ring systems :
containing 1 : 10 : 16 : 22 : 28 :

G1:[*1],[*2],[*3],[*4]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 40:CLASS 41:Atom 42:Atom 43:Atom
44:Atom 45:Atom 46:Atom

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 17:21:29 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED 5 ITERATIONS

5 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 5 TO 234

PROJECTED ANSWERS: 5 TO 234

L2 5 SEA SSS SAM L1

=> => s l1 sss ful

FULL SEARCH INITIATED 17:21:56 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 42 TO ITERATE

100.0% PROCESSED 42 ITERATIONS

39 ANSWERS

SEARCH TIME: 00.00.01

L3 39 SEA SSS FUL L1

=> => s l3

L4 1 L3

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:319891 CAPLUS
 DN 134:340507
 TI Thiazole and imidazo[4,5-b]pyridine compounds with MAP kinase inhibitory activity and their pharmaceutical use as antiinflammatories and immunosuppressants
 IN Revesz, Laszlo
 PA Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
 SO PCT Int. Appl., 82 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001030778	A1	20010503	WO 2000-EP10528	20001025
	W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
	EP 1224185	A1	20020724	EP 2000-969551	20001025
	R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL		
	JP 2003512467	T2	20030402	JP 2001-533132	20001025
	US 6608072	B1	20030819	US 2002-111233	20020422
	US 2004082604	A1	20040429	US 2003-601690	20030623
PRAI	GB 1999-25441	A	19991027		
	GB 1999-26173	A	19991104		
	WO 2000-EP10528	W	20001025		
	US 2002-111233	A3	20020422		
OS	MARPAT 134:340507				
AB	Title compds. I and II and their pharmaceutically acceptable and cleavable esters and acid addition salts are disclosed [wherein: R1 = pyrimidyl or pyridyl; X = N(R')Y, O, or S; R2 = (un)substituted Ph; R3 = H, (un)substituted amino, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl; R4 = (un)substituted alkyl, aryl, heteroaryl, or cycloalkyl; R' = H, alkyl, aryl, heteroaryl, etc.; Y = alkylene, bond]. I and II are MAP kinase inhibitors, useful pharmaceutically for treating diseases mediated by TNF α and IL-1, such as rheumatoid arthritis and diseases of bone metabolism, e.g., osteoporosis. Claims cover the use of the compds. as antiinflammatories and immunosuppressants. Over 30 synthetic examples are given. For instance, cyclocondensation of 2,3-diamino-6-chloropyridine with 4-fluorobenzoic acid gave 5-chloro-2-(4-fluorophenyl)imidazo[4,5-b]pyridine, which was N-heteroarylated by 2-methylthio-4-iodopyrimidine. The product was oxidized to a sulfoxide, which was aminated with cyclopentylamine. Vinylation of the chloride, and addition of piperidine to the vinyl compound, gave invention compound III. The invention compds. had typical IC ₅₀ values against p38 MAP kinase from 100 nM down to 5 nM or less. The compds. also inhibited TNF- α production in lipopolysaccharide-stimulated mice by 50% or more at 10 mg/kg orally.				
IT	337902-43-9P, 2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(4-pyridyl)imidazo[4,5-b]pyridine 337902-46-2P, 2-(4-Fluorophenyl)-1-[2-[(1-(S)-phenylethyl)amino]-4-pyrimidinyl]-5-(1-piperazinyl)imidazo[4,5-b]pyridine 337902-50-8P,				



2-(4-Fluorophenyl)-1-[2-[(1-(S)-phenylethyl)amino]-4-pyrimidinyl]-5-(4-methyl-1-piperazinyl)imidazo[4,5-b]pyridine **337902-65-5P**,
 2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-[[1-(ethoxycarbonyl)piperidin-4-yl]amino]imidazo[4,5-b]pyridine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of thiazoles and imidazopyridines as MAP kinase inhibitors)

RN 337902-43-9 CAPLUS


CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazo[4,5-b]pyridin-1-yl]- (9CI) (CA INDEX NAME)



RN 337902-46-2 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-5-(1-piperazinyl)-1H-imidazo[4,5-b]pyridin-1-yl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 337902-50-8 CAPLUS


CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-5-(4-methyl-1-piperazinyl)-1H-imidazo[4,5-b]pyridin-1-yl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 337902-65-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[1-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-1H-imidazo[4,5-b]pyridin-5-yl]amino]-, ethyl ester (9CI)
(CA INDEX NAME)



IT 337902-37-1P, 2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(2-piperidinoethyl)imidazo[4,5-b]pyridine
337902-38-2P, 2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-[2-(N,N-diethylamino)ethyl]imidazo[4,5-b]pyridine
337902-39-3P, 2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(2-morpholinoethyl)imidazo[4,5-b]pyridine
337902-40-6P, 2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(2-isopropylaminoethyl)imidazo[4,5-b]pyridine
337902-41-7P, 2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(2-pyrrolidinoethyl)imidazo[4,5-b]pyridine
337902-42-8P, 2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(3-pyridyl)imidazo[4,5-b]pyridine 337902-44-0P,
2-(4-Fluorophenyl)-1-[2-[(1-(S)-phenylethyl)amino]-4-pyrimidinyl]-5-aminoimidazo[4,5-b]pyridine 337902-45-1P, 2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-aminoimidazo[4,5-b]pyridine
337902-47-3P, 2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(1-piperazinyl)imidazo[4,5-b]pyridine 337902-48-4P
, 2-(4-Fluorophenyl)-1-(2-cyclobutylamino-4-pyrimidinyl)-5-(1-



piperazinyl)imidazo[4,5-b]pyridine 337902-49-5P,
 2-(4-Fluorophenyl)-1-(2-cyclopropylamino-4-pyrimidinyl)-5-(1-piperazinyl)imidazo[4,5-b]pyridine 337902-51-9P,
 2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(4-methyl-1-piperazinyl)imidazo[4,5-b]pyridine 337902-52-0P,
 2-(4-Fluorophenyl)-1-(2-cyclobutylamino-4-pyrimidinyl)-5-(4-methyl-1-piperazinyl)imidazo[4,5-b]pyridine 337902-53-1P,
 2-(4-Fluorophenyl)-1-(2-cyclopropylamino-4-pyrimidinyl)-5-(4-methyl-1-piperazinyl)imidazo[4,5-b]pyridine 337902-54-2P,
 2-(4-Fluorophenyl)-1-[2-[(1-(S)-phenylethyl)amino]-4-pyrimidinyl]-5-[4-(2-hydroxy-2-methylpropyl)-1-piperazinyl]imidazo[4,5-b]pyridine 337902-55-3P,
 2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-[4-(2-hydroxy-2-methylpropyl)-1-piperazinyl]imidazo[4,5-b]pyridine 337902-56-4P,
 2-(4-Fluorophenyl)-1-(2-cyclobutylamino-4-pyrimidinyl)-5-[4-(2-hydroxy-2-methylpropyl)-1-piperazinyl]imidazo[4,5-b]pyridine 337902-57-5P,
 2-(4-Fluorophenyl)-1-(2-cyclopropylamino-4-pyrimidinyl)-5-[4-(2-hydroxy-2-methylpropyl)-1-piperazinyl]imidazo[4,5-b]pyridine 337902-58-6P,
 2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(4-piperidinyl)imidazo[4,5-b]pyridine 337902-59-7P,
 2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(1-methyl-4-piperidinyl)imidazo[4,5-b]pyridine 337902-60-0P,
 2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-[1-(2-hydroxy-2-methylpropyl)-4-piperidinyl]imidazo[4,5-b]pyridine 337902-61-1P,
 2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(benzylamino)imidazo[4,5-b]pyridine 337902-62-2P,
 2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(morpholino)imidazo[4,5-b]pyridine 337902-63-3P,
 2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(3-fluorophenylamino)imidazo[4,5-b]pyridine 337902-64-4P,
 2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(pyrid-4-ylamino)imidazo[4,5-b]pyridine 337902-66-6P,
 2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(piperidin-4-ylamino)imidazo[4,5-b]pyridine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of thiazoles and imidazopyridines as MAP kinase inhibitors)

RN 337902-37-1 CAPLUS

CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-5-[2-(1-piperidinyl)ethyl]-1H-imidazo[4,5-b]pyridin-1-yl]- (9CI) (CA INDEX NAME)





RN 337902-38-2 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-5-ethanamine, 1-[2-(cyclopentylamino)-4-



10/601,690

pyrimidinyl]-N,N-diethyl-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)





RN 337902-39-3 CAPLUS

CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-5-[2-(4-morpholinyl)ethyl]-1H-imidazo[4,5-b]pyridin-1-yl]- (9CI) (CA INDEX NAME)



RN 337902-40-6 CAPLUS



CN 1H-Imidazo[4,5-b]pyridine-5-ethanamine, 1-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 337902-41-7 CAPLUS



CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-5-[2-(1-pyrrolidinyl)ethyl]-1H-imidazo[4,5-b]pyridin-1-yl]- (9CI) (CA INDEX NAME)

10/601,690



RN 337902-42-8 CAPLUS


CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-5-(3-pyridinyl)-1H-imidazo[4,5-b]pyridin-1-yl]- (9CI) (CA INDEX NAME)



RN 337902-44-0 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-(4-fluorophenyl)-1-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



10/601,690



RN 337902-45-1 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 1-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)





RN 337902-47-3 CAPLUS

CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-5-(1-piperazinyl)-1H-imidazo[4,5-b]pyridin-1-yl]- (9CI) (CA INDEX NAME)



RN 337902-48-4 CAPLUS



CN 2-Pyrimidinamine, N-cyclobutyl-4-[2-(4-fluorophenyl)-5-(1-piperazinyl)-1H-imidazo[4,5-b]pyridin-1-yl]- (9CI) (CA INDEX NAME)



RN 337902-49-5 CAPLUS



10/601,690

CN 2-Pyrimidinamine, N-cyclopropyl-4-[2-(4-fluorophenyl)-5-(1-piperazinyl)-1H-imidazo[4,5-b]pyridin-1-yl]- (9CI) (CA INDEX NAME)





RN 337902-51-9 CAPLUS

CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-5-(4-methyl-1-piperazinyl)-1H-imidazo[4,5-b]pyridin-1-yl]- (9CI) (CA INDEX NAME)





RN 337902-52-0 CAPLUS

CN 2-Pyrimidinamine, N-cyclobutyl-4-[2-(4-fluorophenyl)-5-(4-methyl-1-piperazinyl)-1H-imidazo[4,5-b]pyridin-1-yl]- (9CI) (CA INDEX NAME)



RN 337902-53-1 CAPLUS


CN 2-Pyrimidinamine, N-cyclopropyl-4-[2-(4-fluorophenyl)-5-(4-methyl-1-piperazinyl)-1H-imidazo[4,5-b]pyridin-1-yl]- (9CI) (CA INDEX NAME)



RN 337902-54-2 CAPLUS



CN 1-Piperazineethanol, 4-[2-(4-fluorophenyl)-1-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-1H-imidazo[4,5-b]pyridin-5-yl]- α,α -dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 337902-55-3 CAPLUS

CN 1-Piperazineethanol, 4-[1-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-1H-imidazo[4,5-b]pyridin-5-yl]- α,α -dimethyl- (9CI) (CA INDEX NAME)





RN 337902-56-4 CAPLUS

1-Piperazineethanol, 4-[1-[2-(cyclobutylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-1H-imidazo[4,5-b]pyridin-5-yl]- α,α -dimethyl-
(9CI) (CA INDEX NAME)





RN 337902-57-5 CAPLUS

CN 1-Piperazineethanol, 4-[1-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-1H-imidazo[4,5-b]pyridin-5-yl]- α,α -dimethyl-
(9CI) (CA INDEX NAME)





RN 337902-58-6 CAPLUS

CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-5-(4-piperidinyl)-1H-imidazo[4,5-b]pyridin-1-yl]- (9CI) (CA INDEX NAME)



RN 337902-59-7 CAPLUS


CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-5-(1-methyl-4-piperidinyl)-1H-imidazo[4,5-b]pyridin-1-yl]- (9CI) (CA INDEX NAME)



10/601,690


RN 337902-60-0 CAPLUS

CN 1-Piperidineethanol, 4-[1-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-1H-imidazo[4,5-b]pyridin-5-yl]- α,α -dimethyl-
(9CI) (CA INDEX NAME)



RN 337902-61-1 CAPLUS



CN 1H-Imidazo[4,5-b]pyridin-5-amine, 1-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 337902-62-2 CAPLUS



CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-5-(4-morpholinyl)-1H-imidazo[4,5-b]pyridin-1-yl]- (9CI) (CA INDEX NAME)

10/601,690





RN 337902-63-3 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 1-[2-(cyclopentylamino)-4-pyrimidinyl]-N-(3-fluorophenyl)-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)





RN 337902-64-4 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 1-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)





RN 337902-66-6 CAPLUS



CN 1H-Imidazo[4,5-b]pyridin-5-amine, 1-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-4-piperidinyl- (9CI) (CA INDEX NAME)



- IT 337902-78-0P, 5-Chloro-2-(4-fluorophenyl)-1-(2-methylthio-4-pyrimidinyl)imidazo[4,5-b]pyridine 337902-79-1P, 5-Chloro-2-(4-fluorophenyl)-1-(2-methylsulfinyl-4-pyrimidinyl)imidazo[4,5-b]pyridine 337902-80-4P, 5-Chloro-2-(4-fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)imidazo[4,5-b]pyridine 337902-81-5P, 2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-vinylimidazo[4,5-b]pyridine 337902-83-7P, 2-(4-Fluorophenyl)-1-(2-methylthio-4-pyrimidinyl)-5-aminoimidazo[4,5-b]pyridine 337902-84-8P, 2-(4-Fluorophenyl)-1-(2-methylsulfinyl-4-pyrimidinyl)-5-aminoimidazo[4,5-b]pyridine 337902-89-3P, 2-(4-Fluorophenyl)-1-(2-methylthio-4-pyrimidinyl)-5-(4-tert-butoxycarbonyl-1-piperazinyl)imidazo[4,5-b]pyridine 337902-90-6P, 2-(4-Fluorophenyl)-1-[2-[(1-(S)-phenylethyl)amino]-4-pyrimidinyl]-5-(4-tert-butoxycarbonyl-1-piperazinyl)imidazo[4,5-b]pyridine 337902-91-7P, 2-(4-Fluorophenyl)-1-(2-methylsulfinyl-4-pyrimidinyl)-5-(4-tert-butoxycarbonyl-1-piperazinyl)imidazo[4,5-b]pyridine
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of thiazoles and imidazopyridines as MAP kinase inhibitors)
- RN 337902-78-0 CAPLUS
- CN 1H-Imidazo[4,5-b]pyridine, 5-chloro-2-(4-fluorophenyl)-1-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)





- RN 337902-79-1 CAPLUS
- CN 1H-Imidazo[4,5-b]pyridine, 5-chloro-2-(4-fluorophenyl)-1-[2-(methylsulfinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)





RN 337902-80-4 CAPLUS

CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-fluorophenyl)-1H-imidazo[4,5-b]pyridin-1-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)



RN 337902-81-5 CAPLUS



CN 2-Pyrimidinamine, N-cyclopentyl-4-[5-ethenyl-2-(4-fluorophenyl)-1H-imidazo[4,5-b]pyridin-1-yl]- (9CI) (CA INDEX NAME)





RN 337902-83-7 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-(4-fluorophenyl)-1-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



10/601,690



RN 337902-84-8 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-(4-fluorophenyl)-1-[2-(methylsulfinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 337902-89-3 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-(4-fluorophenyl)-1-[2-(methylthio)-4-pyrimidinyl]-1H-imidazo[4,5-b]pyridin-5-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 337902-90-6 CAPLUS

10/601,690


CN 1-Piperazinecarboxylic acid, 4-[2-(4-fluorophenyl)-1-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-1H-imidazo[4,5-b]pyridin-5-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 337902-91-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-(4-fluorophenyl)-1-[2-(methylsulfinyl)-4-pyrimidinyl]-1H-imidazo[4,5-b]pyridin-5-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/601,690

=> => d his

(FILE 'HOME' ENTERED AT 17:20:54 ON 06 JUL 2004)

FILE 'REGISTRY' ENTERED AT 17:21:00 ON 06 JUL 2004

L1 STRUCTURE UPLOADED
L2 5 S L1 SSS SAM
L3 39 S L1 SSS FUL

FILE 'CAPLUS' ENTERED AT 17:22:12 ON 06 JUL 2004

L4 1 S L3

FILE 'CAOLD' ENTERED AT 17:22:37 ON 06 JUL 2004

=> s l3

L5 0 L3

=> log y

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

FULL ESTIMATED COST

0.42

161.93

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE
ENTRY

TOTAL
SESSION

CA SUBSCRIBER PRICE

0.00

-0.74

STN INTERNATIONAL LOGOFF AT 17:22:48 ON 06 JUL 2004